Numerous RCTs8e24 have shown consistent benefits
with statins in reduction of mortality and cardiovascular events, especially in the diabetic population, in which
cardiovascular disease is the leading cause of mortality. In contrast, a recent meta-analysis revealed that statin therapy
is associated with an increased risk for developing DM.4 Moreover, a newly published meta-analysis showed a dosedependent
effect, with a 12% higher relative risk for developing DM on intensive-dose statin therapy compared
with moderate-dose therapy.5 Potential molecular explanations or the increased risk for DM observed with statin
therapy include modifications in insulin signaling in peripheral tissues, exacerbating insulin resistance, and/or
interaction with pancreatic b-cell function, impairing insulin secretion.25 Further suggested mechanisms influencing the
risk for DM with statins are the power of particular statins to reduce cholesterol concentration and the fact that patients